Roche Chairman Christoph Franz remains confident the Swiss drugmaker can offset revenue declines from patent expired medicines with new drugs, according to an interview published on Sunday in the Swiss newspaper NZZ am Sonntag.
“When I look at the number of medicines we have launched over the past two years, then we’re on the right track,” Franz told the newspaper. “We’ve had six medicines approved by regulators over this time period.”
Among the drugs Franz includes in this group are multiple sclerosis drug Ocrevus, cancer immunotherapy Tecentriq and hemophilia medicine Hemlibra, all of which are expected to have peak sales of well over $1 billion annually.
Roche is counting on these and other medicines to help replace revenue from its $20 billion-per-year trio of Avastin, Herceptin and Rituxan whose patents have expired or will shortly, exposing them to cheaper competition.
Franz also told the newspaper that the United States, where prices for drugs are among the world’s highest, is supporting the bulk of the research and development cost for new, innovative drugs.
Asked if U.S. President Donald Trump’s pledge this year to tackle high drug prices will have an impact, Franz acknowledged that there could be a hit to the “innovation premium” that U.S. insurers and other funders pay for new drugs in America.
Radical changes to the model governing how medicines are reimbursed in the United States would likely lead to job cuts, he said.
“To put it bluntly, if the Americans were to adopt the Swiss price system, Roche would have to cut thousands of research jobs, also in Switzerland,” Franz said.
By John Miller
Source: Reuters
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.
